CELLECTAR BIOSCIENCES INC

CLRB is the Nasdaq ticker symbol for Cellectar Biosciences, Inc., a clinical-stage biopharmaceutical company. The company focuses on developing targeted cancer therapies using its proprietary phospholipid drug conjugate delivery platform. As a small-cap biotech, CLRB's stock reflects the company's pipeline progress, clinical trial outcomes, and capital position rather than commercial product sales. Investors typically track CLRB news for trial updates and regulatory milestones.

The 52-week range shows the lowest and highest prices CLRB traded at over the past year, giving context for its current price level. Because this changes with market activity, the exact high and low for CLRB are best taken from the latest data displayed on this page. Comparing the current price against that range can help investors gauge where CLRB sits relative to its recent trading history.

Since CLRB is a clinical-stage biotech without meaningful product revenue, traditional metrics like the P/E ratio often do not apply. Instead, investors may review cash and cash equivalents, burn rate, enterprise value, and pipeline valuation potential. Market capitalization relative to expected clinical milestones can also be informative. Analysts sometimes estimate future revenue potential from drug candidates, though these projections carry significant uncertainty.

CLRB trades on the Nasdaq under that ticker and can be bought through most brokerage accounts, including traditional and online platforms. You would place a market or limit order for CLRB shares during regular trading hours. Some brokers also allow extended-hours trading. The minimum amount depends on the share price at the time of purchase and whether fractional shares are available through your broker.

Cellectar Biosciences does not currently pay a dividend, as is typical for clinical-stage biotechnology companies that reinvest capital into research and development. CLRB's cash is generally directed toward advancing its pipeline of targeted cancer therapies rather than returning capital to shareholders. Investors interested in dividends would need to look at other companies in the biotech sector that have commercial products and positive cash flow.

Key metrics for CLRB include cash and cash equivalents, quarterly cash burn, and the company's runway to fund operations. Because CLRB is pre-revenue, operating expenses and net loss are also important, along with progress in clinical trials for its drug candidates. Investors often track financing activities, such as equity raises, since they can affect share count and dilution. These figures are reported in CLRB's quarterly and annual filings.